Highlight
This study demonstrates that neoadjuvant therapy (NAT) significantly modifies established prognostic factors for overall survival in pancreatic ductal adenocarcinoma (PDAC). Personalized predictive models based on treatment context (NAT vs chemotherapy-naïve) improve the accuracy of patient prognostication post-resection.
Key prognostic markers differ markedly between groups, with normalization of carbohydrate antigen 19-9 and treatment response grade being critical for NAT patients, while traditional pathologic features remain dominant predictors in chemo-naïve patients.
